1)Iwahashi C, Okuno K, Hashida N et al:Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals. Jpn J Ophthalmol 59:157-163, 2015
2)Urzua CA, Velasquez V, Sabat P et al:Earlier immunomodulatory treatment is assosiated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 93:e475-e480, 2015
3)望月 學・後藤 浩・川島秀俊・他:非感染性ぶどう膜炎におけるネオーラルの安全使用マニュアル(2013年版)
).あたらしい眼科34:489-492,2017
5)白樫祐介・杉浦 丹・藤本篤嗣・他:アトピー性皮膚炎における低用量シクロスポリン1日1回食前投与の有用性.日皮会誌121:3343-3348,2011
6)春田真実・吉岡茉依子・福富 啓・他:Vogt-小柳-原田病に対する低用量シクロスポリン投与の効果.日眼会誌121:474-479,2017
7)上野雅代・山内淳史・小河原悟・他:難治性ネフローゼ症候群患者に対するシクロスポリンの最適投与法.医療薬学33:831-839,2007
8)梅澤慶紀・赤坂江美子・馬渕智生・他:皮膚科領域における免疫抑制薬と個別療法.Organ Biology 24:43-53,2017
9)Choudhry S, Bagga A, Hari P:Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome:a randomized controlled trial. Am J Kidney Dis 53:760-769, 2009
10)Jabs DA, Rosenbaum JT, Foster CS et al:Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders:recommendations of an expert panel. Am J Ophthalmol 130:492-513, 2000
11)Couto C, Schlaen A, Frick M et al:Adalimumab treatment in patients with Vogt-Koyanagi-Harada disease. Ocular Immunology and Inflammation 1-5. DOI:10.1080/09273948.2016.1236969
12)Iijima K, Hamahira K, Tanaka R et al:Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 61:1801-1805, 2002
13)Menter A, Korman NJ, Elmets CA et al:Guidelines of care for the management of psoriasis and psoriatic arthritis:section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 61:451-485, 2009
14)Pathirana D, Ormerod AD, Saiag P et al:Europea S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23:Suppl 2:1-70, 2009
による乾癬治療のガイドライン.臨皮55:107-113,2001